INTRODUCTION
The Signal Transducer and Activator of Transcription 3 (STAT3) is an important regulator of many biological processes including proliferation, survival, inflammation and immune responses (1, 2) . STAT3 mediates these processes by responding to ligands such as growth factors (i.e. EGF, PDGF) and cytokines (i.e. IL-6, IFN-gamma) which activate STAT3 to translocate to the nucleus and regulate the expression of a number of genes (1, 2) . For example, the binding of EGF to its receptor results in tyrosine phosphorylation of the EGF receptor and subsequent recruitment of STAT3 through the binding of the STAT3-SH2 domain to phospho-tyrosines 1068 and 1086 on the receptors (3) . Similarly, non-receptor tyrosine kinases such as JAK2 and Src which are part of non-tyrosine kinase receptor complexes (i.e. IL-6 receptor complex) phosphorylate a specific tyrosine on STAT3 which in turn induces STAT3-STAT3 dimerization through two reciprocal phosphotyrosine-SH2 binding interactions (4) . The activated STAT3 dimers translocate to the nucleus where they bind to specific DNA sequences on the promoters of the genes regulated by STAT3 (1, 2) . Under physiological normal conditions, this STAT3 activation is rapid (within 2 minutes of ligand stimulation) and transient (lost within a few hours due to dephosphorylation).
In contrast, STAT3 is found persistently tyrosine phosphorylated and constitutively activated in the majority of cancers including pancreatic, breast, lung, prostrate, ovarian, colon, gastric and head and neck cancers as well as melanoma, leukemia, multiple myeloma and lymphoma (4) . Constitutively-activated STAT3 is believed to contribute to malignant transformation at several levels (5) . These include uncontrolled proliferation through activation of several cell cycle regulators such as cyclin D1 and c-Myc as well as evasion of apoptosis by inducing the expression of several anti-apoptotic proteins such as BclxL, Bcl-2, Mcl-1 and survivin. STAT3 also activates the expression of proteins involved in other hallmarks of cancer such as invasion and metastasis (i.e. expression of MMPs) and angiogenesis (i.e. expression of VEGF) (2, 4) . The fact that STAT3 regulates the expression of a number of genes involved in oncogenesis makes it an attractive and promising target for cancer therapy (6, 7) . Validation of STAT3 as a target for cancer drug discovery comes from several lines of evidence. For example, a genetically engineered mutant of STAT3 (STAT3-C) that forms a constitutively dimerized STAT3 through disulfide binds is oncogenic (8) . On the other hand, a dominant-negative variant of STAT3, STAT3ȕ, blocks tumor growth by inhibiting STAT3 in tumors where STAT3 is constitutively activated (9, 10) . Several approaches have been proposed to suppress constitutive activation of STAT3. These include those inhibiting STAT3 tyrosine phosphorylation (i.e. inhibition of JAK2 or Src), STAT3 recruitment to the receptor and dimerization (i.e. phosphotyrosine peptide mimics that binds the SH2 domain of STAT3), STAT3 nuclear translocation and STAT3-DNA binding and transcriptional activation (6, 7) . We have focused our efforts on identifying small molecules capable of disrupting the phosphotyrosine-SH2 binding interactions of STAT3 as potential dimerization inhibitors. Here we report on a novel STAT3-STAT3 dimerization inhibitor that selectively inactivates STAT3 and suppresses STAT3-dependent malignant transformation.
MATERIALS AND METHODS

Cells and reagents
Human breast cancer (MDA-MB-468, MDA-MB-231, MDA-MB-453), lung cancer (A549, H358, H460) cells, human non-tumorigenic epithelial cells (MCF10A) and human embryonic kidney cells (HEK293)
were obtained from ATCC (the American Type Culture Collection, Manassas, VA, USA). These cell lines have not been authenticated. HEK 293 cell lines with stable transfection of HA-STAT3 and FLAG-STAT3 were generated as described below. Cells were grown in Dulbecco's modified Eagle's medium (DMEM), RPMI 1640, and DMEM/F-12 containing 10% heat-inactivated fetal bovine serum. MCF10A was cultured in DMEM/F12, supplemented with 5% horse serum (Invitrogen, CA, USA), hydrocortisone (0.5 μg/ml), mouse epidermal growth factor (EGF; 20 ng/ml), insulin (10 μg/ml), cholera toxin (100 ng/ml, Sigma, MO, USA). Primary antibodies against pY705STAT3, pAKT, AKT, pErk1/2, Erk, MMP9, and Cyclin D1 were purchased from Cell Signaling Technology (Danvers, MA). Primary antibodies against STAT3, Bcl-xL, Survivin, HA (anti-mouse), and HA (anti-rabbit) were purchased from Santa Cruz Biotech (Santa Cruz, CA). Primary antibody against FLAG was purchased from Sigma (St. Louis, MO, USA).
Generation of HA-STAT3 and FLAG-STAT3 constructs and generation of HEK293 cells stably expressing HA-STAT3 and FLAG-STAT3
FLAG-Stat3 plasmid was obtained from Addgene (Cambridge, MA, USA). HA-Stat3 DNA was amplified from FLAG-Stat3 using PCR with HA-pcDNA3 as a vector as described for RhoB by our lab (11) .
The primers used for PCR were STAT3F-BamH1 CGCGGATCCGCCACCATGGCTCAGTGGAACCAGCTG and STAT3R-EcoR1
CCGGAATTCTCACATGGGGGAGGTAGCACA. The PCR product was digested with BamH1 and EcoR1, and cloned into HA-pcDNA3 vector, further confirmed by sequencing. Ratio (1:1) of pFLAG-STAT3 and pHA-STAT3 plasmid DNAs were co-transfected into HEK-293 cells, and stable G418-resistant (800ug/ml) clones were selected. Transfections were carried out with LipofectAmine Plus (Invitrogen, Carlsbad, CA), according to the manufacturer's protocol.
Nuclear Extract Preparation and STAT3 Filter Plate Assay
Nuclear extract preparation was carried out as previously described (12) .The STAT3-DNA binding filter plate assay was performed following the manual of the filter plate assay kit (Signosis, Sunnyvale, CA), as described previously for NFkB (13) . The TF Binding buffer was mixed with the STAT3 probe (biotin labeled STAT3 DNA binding sequence) and nuclear extract and incubated at 16°C for 30 minutes to form the STAT3-DNA complex. The STAT3-DNA complex was then separated from free probe by using a filter plate. After several steps of binding and washing, bound STAT3 probe is retained on the filter in the 
Fluorescence Polarization Assay
Fluorescence polarization (FP) assay was conducted based on fluorescence signal differences between free and STAT3-bound fluorescently labeled peptide as described by Schust and Berg (14, 15 SD is the standard deviation and mP is the average of fluorescence polarization.
STAT3 Transcriptional Activity
MDA-MB-468 cells were plated into 12-well plate with 4x10 5 cells per well. The cells were transiently transfected with pLucSRE, pLucTKS3 or STAT3-C with ȕ-gal and then were treated with vehicle, S3I-1756 or S3I-1757 for 48 hours. Then cytosolic extracts of equal total protein were prepared from S3I-1757-treated or -untreated and analyzed for luciferase activity using a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA) described by us previously (16) . 
Co-localization
MTT Assay
MTT assay was performed exactly as described by our lab (17) hours. After incubation, freshly prepared MTT (3mg/ml) in 1XPBS was added to each well and incubated for 3 hours and the plate was read at 570 nm.
Colony Survival Assay
Cells were cultured at 500 cells per well in 12-well plate with regular growth medium. Cells were treated by vehicle, and 1757 at 50 μM, 100 μM and 200 μM on the following day. And Cells were allowed to grow for 2-3 weeks until the colonies were visible. 3mg/ml MTT in PBS buffer (Sigma, St. Louis, MO, USA) was used to stain the colonies for 4 hours.
Wound Healing Assay
A549, MDA-MB-231 and H460 cells were seeded at 6 x 10 5 cells per dish into 60mm plate and allowed to grow overnight. Wounds were made the following day by scratching the cells with pipette tips (1-10μL 
Invasion Assay
Invasion assay was performed in BD BioCoat™ Matrigel™ Invasion Chamber in 24-well plates. A549, MDA-MB-468, MDA-MB-231 and H460 cells were seeded at 25,000 cells/ insert in the top chamber over the Matrigel. The bottom chamber contains 20% FBS as the "chemoattractant". Vehicle, S3I-1756, or S3I-1757 were added the following day. The cells were incubated for 48 hours, after which the cells in the top chamber were carefully removed and the filter membranes containing the invaded cells on the outside of the filter were fixed with methanol, stained with crystal violet and photographed.
Anchorage Independent Growth by Soft Agar Assay
Soft agar colony formation assays were performed in 12-well plate as described previously by us (17) .
Briefly, cells were seeded at 2000 cells per well in regular growth media containing 0.3% agar (Sigma) and S3I-1757 was added the following day. Colonies were allowed to grow for 3-4 weeks, and quantified by staining with 1mg/mL MTT (Sigma, St. Louis, MO, USA) overnight.
Molecular docking and Modeling
Briefly, the GLIDE docking software (available from Schrödinger, Inc.) was employed to dock small molecule 3D structures from NCI Plated Set to the ApY*LK site derived from the X-ray crystal structure of the STAT3 dimer bound to DNA (18). Schrödinger's Maestro 9.1 was used as the primary graphical user interface. Schrödinger's LigPrep 2.41 was used to prepare molecules for docking and Schrödinger's Protein Preparation workflow was used in the preparation of the protein structure. Schrödinger's GLIDE 5.6 was used for the generation of grid files and docking. Initially, structures were subjected to docking with GLIDE SP and then the structures from each SP job were subjected to GLIDE XP docking.
Generally at least three poses were saved for each run for visual inspection. PyMol (Schrodinger, Inc.) was used for graphical presentation of the results in the figures. 
Effects of inhibitors on the levels of P-STAT3, P-Erk
Immunoprecipitation and immunoblotting
HEK-293/FLAG-STAT3/HA-STAT3 cells were treated for 4 h with vehicle, S3I-1757, S3I-1756, AcG{pTYR}LPQTV-AAVLLPVLLAAP-NH2 or Ac-GYLPQTV-AAVLLPVLLAAP-NH2 and then lysed in 20mM Tris-HCl (pH 7.4), 5mM EDTA, 10mM Na4P2O7, 100mM NaF, 2mM Na3VO4, 1% NP-40,1mM PMSF and 10mg/ml aprotinin. For EGF stimulation group, HEK-293/FLAG-STAT3/HA-STAT3 cells were treated by 100ng/ml EGF for 30 minutes before making cell lysate. Protein A or G agarose (EMD Millipore, Billerica, MA, USA) was washed twice with PBS and restore to 50% slurry with PBS. 500 ȝg of lysate were pre-cleared by mixture of protein A and protein G -agarose for 1 h at 4°C and then remove protein A and G-agarose by centrifuge at 1300rpm for 3minutes. And then 500 ȝg of lysate was immunoprecipitated with 50 ng of HA antibody overnight at 4°C on shaker and then capture the immunocomplex by adding 100 ȝl Protein A and G agarose/sepharose bead slurry for 1 hour at 4°C.
Samples were washed five times with lysis buffer and then boiled in 5× SDS-PAGE sample buffer and run on SDS-PAGE gel. Protein was transferred to nitrocellulose membrane and then blotted as described above for HA, FLAG, pSTAT3, EGFR, and STAT3.
RESULTS
S3I-1757 inhibits the binding of fluorescein-labelled GpYLPQTV phosphotyrosine peptide to
STAT3 much more potently than its closely related analogue S3I-1756
In an effort to identify STAT3-STAT3 dimerization disruptors, we have undertaken a major chemistry effort based on structure activity relationship (SAR) studies using our previously published S3I-201 compound (16) as a starting point. These SAR studies identified several STAT3 inhibitors (19) . In the present manuscript, we focused on S3I-1757 and its closely related analogue S3I-1756 ( Figure 1A ). We first determined the potency of these molecules to disrupt the binding of STAT3 to fluorescein-labelled GpYLPQTV phosphotyrosine peptide by fluorescence polarization assays as described under Methods (the GpYLPQTV phosphotyrosine peptide corresponds to amino acids 903-909 from the gp-130 subunit of the IL-6 receptor and is known to bind the STAT3-SH2 domain (20, 21) ). Figure 1A shows that S3I-with an IC50 value of 13.5 ± 0.5 μM. In contrast, the closely related analogue S3I-1756 had little effects with concentrations as high as 400 μM ( Figure 1A ). This data shows that replacing the cyclohexyl group in S3I-1757 with a methoxy group as in S3I-1756 resulted in great (over 26-fold) loss of potency to disrupt STAT3 phosphotyrosine-peptide binding. for the salicylate phenyl group and an N to phenyl ring centroid distance of 3.5 Å for the phenyl group to which the cyclohexyl substituent is attached); (c) S3I-1756 forms 2 weaker cation-π interactions with Lys 591 (with an N to phenyl ring centroid distance of 4.6 Å for the salicylate phenyl group and an N to phenyl ring centroid 4.5 Å for the phenyl group to which the phenoxy group is attached); (d) the surface rendering of the protein in Figure 1B shows that the cyclohexyl substituent of S3I-1757 is buried in a pocket with a rather negative electrostatic potential whereas the phenoxy substituent of S3I-1756 is similarly buried, although not as deeply and the πelectron system of the phenoxy substituent would not interact favorably with this negatively charged environment; (e) the methoxy-phenyl substituent of S3I-1756 is mostly solvent exposed and forms almost no interactions with the protein.
Molecular modeling suggests that
Co-immunoprecipitation and co-localization experiments reveal that S3I-1757 but not S3I-1756 disrupts intracellular STAT3-STAT3 dimerization and STAT3-EGFR binding
The data from the FP assays of Figure 1A coupled with the molecular modeling results of Figure 1B suggest that S3I-1757 inhibits STAT3 dimerization. However, the FP assay only measured the ability of S3I-1757 to displace the 7 amino acid fluorescein-labelled GpYLPQTV phosphotyrosine peptide from the SH2 domain of STAT3 protein in vitro. Therefore, we next determined if the intracellular reciprocal cells that stably co-express HA-STAT3 and FLAG-STAT3 and using these cells for coimmunoprecipitation and co-localization experiments as described under Methods. Figure 2A shows that FLAG-STAT3 co-immunoprecipitated with HA-STAT3 in HEK293 cells that co-express FLAG-STAT3
and HA-STAT3 but not in empty vector-transfected HEK293 cells (Vector). We validated this assay by treating the FLAG-STAT3/HA-STAT3 HEK293 cells with tyrosine phosphorylated or nonphosphorylated GYLPQTV peptide fused to a membrane-translocating sequence (MTS) to allow cell uptake. Figure 2A Therefore, using methods that investigated STAT3 intracellular dimerization with tagged STAT3 
proteins, we demonstrated that STAT3-STAT3 protein-protein binding in intact cells was disrupted with a small molecule designed to disrupt phosphotyrosine binding to STAT3-SH2 domain. 
S3I-
S3I-1757, but not S3I-1756, inhibits STAT3-but not SRE-dependent transcriptional activation:
STAT3-C rescues this inhibition
We next evaluated the ability of S3I-1757 to inhibit STAT3-dependent transcriptional activation using a luciferase reporter assays. To this end, MDA-MB-468 cells were transiently co-transfected with a STAT3-responsive promoter-firefly luciferase reporter (pLucTKS3) and ȕ-gal reporter used to normalize the transfection efficacy. To determine the selectivity of S3I-1757 to suppress STAT3-dependent over STAT3-independent transcriptional activation, MDA-MB-468 cells were also co-transfected with SRE promoter-renilla luciferase reporter (pLucSRE) and ȕ-gal reporter. Figure 4A shows that, compared to mock transfected cells, cells transfected with STAT3-responsive reporter (pLucTKS3) had increased luciferase activity in the absence of drug treatment. In contrast, less luciferase activity was observed when the cells were treated with S3I-1757 but not S3I-1756. S3I-1757 inhibited STAT3-dependent but not STAT3-independent transcriptional activity as demonstrated by the minimal effect it had on SREdriven luciferase activity ( Figure 4A ). We next used a constitutively-dimerized mutant form of STAT3, STAT3-C, to further demonstrate the STAT3-dependence of the inhibition with S3I-1757. STAT3-C spontaneously dimerizes via disulfide bonds in the absence of tyrosine phosphorylation (see Introduction section), and is therefore not predicted to be inhibited by a small molecule that is designed to mimic phosphotyrosine binding. Figure 4A shows that transfection of MDA-MB-468 cells with STAT3-C increased the transcriptional activity of the STAT3-but not the SRE-responsive promoter, and rescued from the S3I-1757 inhibition. Figures 1, 2, 3 and 4A demonstrated that S3I-1757 inhibits STAT3 dimerization, accumulation of nuclear P-Y705-STAT3, STAT3-DNA binding and transcriptional activity. We next determined if the ability of STAT3 to regulate the expression of its target genes is affected by S3I-1757. First, we confirmed that S3I-1757 inhibits the phosphorylation of STAT3-Y705 by western blotting and determined whether this is selective. To this end, MDA-MB-468 cells were treated with vehicle, S3I-1756 or increasing concentration of S3I-1757 and processed for western blotting as described under Methods. Figure 4B shows that S3I-1757, but not S3I-1756, inhibited the phosphorylation of STAT3-Y705 in a concentrationdependent manner starting at 50 μM. This inhibition was selective for STAT3 over Akt and Erk1/2 phosphorylation. Figure 4B also shows that S3I-1757, but not S3I-1756, inhibited the expression of STAT3 target genes such as the anti-apoptotic proteins Bcl-xL and survivin, the cell cycle protein cyclin D1 and the pro-metastatic protein MMP9. Figure 7A shows that in the absence of drug, the cells migrated within 24 hours to fill the scratched area. S3I-1757, but not S3I-1756, treatment prevented this migration in cells with persistently activated STAT3 (MDA-MB-231 and A-549). In contrast, the migration of H460 (with low levels of P-STAT3) was minimally affected by the same treatment condition. Finally, the ability of S3I-1757 to inhibit selectively invasion was determined as described under Methods. Figure 7B shows that S3I-1757 but not S3I-1756, inhibited invasion in MDA-MB-468, MDA-MB-231 and A-549 but not in H-460 cells.
S3I-1757 but not S3I-1756 decreases the tyrosine phosphorylation of STAT3 selectively over the phosphorylation of Akt and Erk1/2, and decreases the expression of genes that are transcriptionally-regulated by STAT3
STAT3-C rescues from S3I-1757 inhibition of gene expression, tumor cell growth, migration and invasion as well as from apoptosis induction
The fact that S3I-1757 but not its inactive analogue S3I-1756 inhibits malignant transformation selectively in cells that harbor hyperactivated STAT3 suggested that S3I-1757 mediates its effects by inhibiting STAT3. To give further support to this suggestion, we determined whether the effects of S3I- 
DISCUSSION
The first demonstration that STAT3 is involved in malignant transformation (12) was reported in 1995 only a year after its discovery (22) . Less than 6 years later peptides and peptide mimics of the phosphotyrosine peptide PpYLKTK that bind STAT3 SH2 domain were shown to inhibit STAT3 dimerization in vitro and STAT3 activity in intact cells (23) . Yet, eleven years later, there are no small molecule STAT3 dimerization inhibitors in clinical trials. One of the major reasons for this is that STAT3-STAT3 dimerization is a protein-protein interaction that involves a large surface area which is difficult to target with drug-like small molecules. The second reason, which is even more challenging, is that the negatively charged phospho-tyrosine which is required for binding to the SH2 domain is difficult to mimic with moieties that can be easily taken up by cells. Nevertheless, because of the critical role of STAT3 in oncogenesis, several groups have put major efforts towards developing STAT3 dimerization inhibitors based on Phospho-peptide mimics as novel anti cancer drugs (6, 7). For example, McMurray and colleagues have succeeded at obtaining cell permeable peptidomimetics of pYLPQ where pY was replaced by phosphocinnamide derivatives to improve peptidase resistance and used the pivaloyloxymethyl prodrug strategy to improve cellular uptake which lead to potent inhibition of STAT3 activity in whole cells (24) . Similarly, Wang and colleagues (25) have also succeeded at designing a conformationally constrained pYLPQTV peptidomimetic with a long hydrocarbon chain to improve cell permeability. Although these are outstanding achievements, there still remain physicochemical challenges concerning the use of phospho-tyrosine peptidomimetics in vivo (7) . Therefore non-peptidic small molecules capable of disrupting STAT3-STAT3 dimerization is an attractive alternative approach to inhibiting STAT3 directly. We have used structure-based virtual screening and identified S3I-201, a 
salicylic acid sulfonamide-based compound, which inhibits STAT3 dimerization in vitro and STAT3 activity in whole cells (16) . Turkson, Gunning and colleagues have subsequently reported on salicylic acid sulfonamide S3I-201 analogues with improved potency (26, 27) . Our recent chemistry efforts resulted in a series of novel non-sulfonamide-containing salicylic acid based compounds (19) . In this manuscript, we have demonstrated that one of these, S3I-1757, inhibited STAT3 dimerization in vitro and in whole cells, STAT3 tyrosine phosphorylation, nuclear accumulation, transcriptional activity and expression of STAT3-regulated genes as well as anchorage-dependent and -independent growth, migration and invasion. 
